BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver vaccines....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | Jan 12, 2018
Clinical News

PharmaMar reports OS data from Phase III of Aplidin for MM

PharmaMar S.A. (Madrid:PHM) reported data for the secondary overall survival (OS) endpoint from the Phase III ADMYRE trial in 255 patients with relapsed or refractory multiple myeloma (MM) evaluating Aplidin plitidepsin plus dexamethasone vs. dexamethasone...
BioCentury | Dec 22, 2017
Clinical News

CHMP recommends against PharmaMar's Aplidin for MM

EMA's CHMP recommended against approval of Aplidin plitidepsin from PharmaMar S.A. (Madrid:PHM) to treat relapsed or refractory multiple myeloma. The committee said it will publish more information on the opinion "shortly." Chugai Pharmaceutical Co. Ltd....
BioCentury | Dec 15, 2017
Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer...
BioCentury | Nov 15, 2016
Distillery Therapeutics

Infectious disease

...INDICATION: Malaria In vitro and mouse studies identified an EEF2 inhibitor that could help treat malaria...
...inhibitor that could help treat malaria. In cultured Plasmodium falciparum , a previously reported quinoline-4-carboxamide-based EEF2...
...malaria. The generics chloroquine and mefloquine are both marketed to prevent and treat malaria. TARGET/MARKER/PATHWAY: Eukaryotic translation elongation factor 2 (EEF2)...
BioCentury | Sep 29, 2016
Targets & Mechanisms

Hitting for the cycle

...PfATP4 . Last year, Merck KGaA licensed a preclinical pan-life cycle stage inhibitor that targets EEF2...
...Inc. (NASDAQ:VRTX), Boston, Mass. Targets and Compounds CYTB - P. falciparum cytochrome B EEF2 - Eukaryotic translation elongation factor 2...
BioCentury | Jun 25, 2015
Translation in Brief

One-stop malaria treatment

...mosquitos that had fed on non-treated mice. Finally, the team discovered that DDD107498 selectively inhibited eukaryotic translation elongation factor 2 (EEF2)...
BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Eukaryotic translation elongation factor 2 kinase (EEF2K) Patient, mouse...
Items per page:
1 - 10 of 14